The results of a recent study that analyzed Warfarin’s impact of restoring sinus rhythm on Warfarin sensitivity has been published on Medscape. The periods examined by researchers included zero to four weeks before the procedures, and an expanded period of four weeks to 3 months after the procedures.
For this study, researchers conducted a retrospective review of the records of AF patients that had undergone a cardioversion or ablation as a means of restoring sinus rhythms. The study lasted for 27 months. The researchers also reviewed information that covered the 3-month periods before and after the procedures. Their goal was to discover which doses of Warfarin were needed to maintain International Normalized Ratio (INR) values (with the current range recommendation being 2.0–3.0). The Warfarin doses were compared with researchers using paired t tests.
The researchers found that the average weekly Warfarin dose in the first four weeks was not significantly different enough from the doses that were given during the expanded postprocedure periods. Basically, researchers discovered that Warfarin dosages that are needed in order to maintain a targeted goal INR of 2.0–3.0 were stable in the month before and after the procedures to convert atrial fibrillation to sinus rhythm. While cardioversion and ablation treatments are commonly viewed by doctors as a safe alternative to drugs like Warfarin and Multaq, the drugs are the most widely used. One of those drugs, however, is only being prescribed when other medications fails. That drug is Multaq, which is made by Sanofi-Aventis. Multaq has been linked to liver failure and worsening of the heart condition, and has spawned numerous lawsuits against its manufacturers.
If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.